AstraZeneca (AZN) stock is in focus as the FDA approves a label expansion for its breast cancer therapy Truqap in prostate ...

For many men with prostate cancer, the word “radiotherapy” still conjures up weeks of daily hospital trips: 20 or more ...

Completion of patient dosing in the registrational Phase 2 clinical trial for 64 Cu-PSMA-I&T - a PET radiopharmaceutical targeting ...

Adding apalutamide to ADT in the adjuvant and neoadjuvant settings improves outcomes in prostate cancer patients undergoing ...

For men with localized prostate cancer, proton therapy looks no better than IMRT when it comes to 3-year biochemical ...

Results of a multicenter clinical trial found that adding the investigational adenoviral-based viral immunotherapy ...

Less is more in the case of this cancer treatment. The most common form of cancer among men in the US, after skin cancer, prostate cancer often comes with traditional treatments that cause difficult ...

Does prostate cancer screening save lives? The Cochrane, an influential group renowned for its gold-standard medical reviews, has previously addressed that question twice, and twice the answer was ‘no ...

JACKSONVILLE, Fla. – It is poised to revolutionize cancer treatment. An experimental drug that targets pancreatic cancer is being fast tracked for approval by the FDA. How promising is this drug’s ...

Please provide your email address to receive an email when new articles are posted on . Improved screening and treatments could reverse global prostate cancer mortality trends. Involving other ...

(WHTM) — A treatment option for prostate cancer patients is now available in the Midstate. The UPMC Hillman Cancer Center in Harrisburg can now provide HDR, or high-dose rate prostate brachytherapy.

ODAC support hinged on biological plausibility for AKT inhibition in PTEN-loss disease, balanced against modest rPFS effect size and absent mature OS advantage. CAPItello-281 used prospective PTEN ...